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Mast Cells Exhibiting Strong 
Cytoplasmic Staining for IgE and 
High Affinity IgE Receptor are 
Increased in IgG4-Related Disease
Kenji Nishida1, Yuka Gion1, Mai Takeuchi1, Takehiro Tanaka2, Tatsuki R. Kataoka3,  
Tadashi Yoshino1 & Yasuharu Sato1,4
Immunoglobulin G4 (IgG4)-related disease is characterized by elevated serum IgG4 levels and 
increased numbers of IgG4-positive cells. However, its pathogenesis is not fully understood. We 
previously suggested that mast cells may play an important role in IgG4-related disease. In this 
study, we confirmed the characteristics of mast cells in IgG4-related lymphadenopathy by using 
immunohistochemistry and dual immunofluorescence. We analyzed 23 cases of IgG4-related 
lymphadenopathy and compared them with 23 cases of non-specific lymphoid hyperplasia. The 
majority of patients with IgG4-related lymphadenopathy had cervical lesions with involvement of other 
organs. Immunohistologically, mast cells with strong cytoplasmic staining for immunoglobulin E and 
high affinity immunoglobulin E receptor were significantly increased in IgG4-related lymphadenopathy 
as compared to those in non-specific lymphoid hyperplasia (mean: 3.83 ± 3.99 cells per high power 
field and 7.14 ± 8.21 cells per high power field, respectively; P = 0.007 and P = 0.011). In addition, dual 
immunofluorescence assay showed that immunoglobulin E and high affinity immunoglobulin E receptor 
staining exhibited a cytoplasmic granular pattern in IgG4-related lymphadenopathy, suggesting 
internalization of the antibodies and receptors. Our findings showed that mast cell activation might be 
involved in the pathogenesis of IgG4-related disease.
Immunoglobulin G4-related disease (IgG4-RD) was initially described in 2001 as sclerosing pancreatitis with 
elevated serum IgG4 levels1, and has subsequently been described in various organ systems, including the biliary 
tree, salivary glands, periorbital tissues, kidneys, lungs, meninges, aorta, breast, prostate, thyroid gland, pericar-
dium, skin, and lymph nodes2. This is a fibro-inflammatory condition characterized by a tendency to form tume-
factive lesions at multiple sites, with a distinctive histopathological appearance, and often, but not always, elevated 
serum IgG4 levels2,3. Although glucocorticoids are effective and the standard therapy for IgG4-RD, the disease is 
known to be likely to relapse during tapering or cessation of the medicine. Yamamoto et al.4 reported that more 
than half of patients with Mikulicz’s disease experience relapse during steroid therapy. Thus, IgG4-RD has been 
deemed incurable in Japan, and investigators have attempted to elucidate its pathogenesis within the last decade.
There are many hypotheses regarding the pathogenesis of IgG4-RD that involve autoimmunity, molecular 
immunity, specific genotypes, intestinal bacterial flora, allergies, and other factors, which are yet to be proven. 
From a histopathological point of view, upregulation of T helper 2 (Th2) (interleukin [IL]-4, IL-5, and IL-13) 
and regulatory T (Treg) (IL-10 and transforming growth factor beta 1) cytokines was detected in affected tis-
sues of patients with autoimmune pancreatocholangitis5, suggesting that the immune reaction mediated by these 
cytokines may be responsible for the lesions. These findings have also been confirmed in salivary glands, ocular 
adnexa, and kidneys6–8. However, to the best of our knowledge, only a few previous reports have investigated the 
mechanism underlying Th2 and Treg activation in IgG4-RD.
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We previously reported a significant upregulation of IL-4, IL-10, IL-13, and transforming growth factor beta 1 
in IgG4-related submandibular gland disease9. These findings in IgG4-related sialoadenitis were consistent with 
those of other previous reports6,10,11. In addition, we discerned that the infiltrating cells expressing Th2 and Treg 
cytokines were histomorphologically similar to mast cells and exhibited strong cytoplasmic staining for immu-
noglobulin E (IgE). Interestingly, although the number of c-kit-positive mast cells was not significantly increased 
in IgG4-related submandibular gland disease as compared to that in sialolithiasis and normal submandibular 
glands, the number of strongly cytoplasmic IgE-positive mast cells was significantly increased in IgG4-related 
submandibular gland disease. Based on these findings, we note mast cells exhibiting strong cytoplasmic staining 
for IgE as a key role in IgG4-RD. However, the underlying mechanisms and immunological significance of strong 
cytoplasmic IgE staining remain unclear.
In this study, we aimed to confirm whether mast cells exhibiting strong cytoplasmic staining for IgE were 
noted in IgG4-related lymphadenopathy cases and to identify the significance of the strong cytoplasmic staining.
Materials and Methods
Patients and samples. Tissue samples were obtained from 23 cases of IgG4-related lymphadenopathy. 
Tissue samples from an equal number of cases (n = 23) of non-specific lymphoid hyperplasia were used as disease 
controls. All slides were jointly reviewed by K.N., M.T., and Y.S. Formalin-fixed paraffin-embedded specimens 
were used for immunohistochemistry and dual immunofluorescence. All tissue samples were obtained with the 
approval of the Institutional Review Board of Okayama University (Okayama, Japan). Informed consent for the 
use of their samples in research was obtained from all patients.
Histological examination and immunohistochemistry. The following methods were carried out in 
accordance with approved guidelines. All experimental protocols were approved by the Institutional Review 
Board at Okayama University.
Excisional biopsies were obtained from lymph node lesions in 23 patients with IgG4-related lymphadenopathy 
and an equal number of patients (n = 23) with non-specific lymphoid hyperplasia. The specimens were fixed in 
10.0% formaldehyde and embedded in paraffin. Serial 4-µm-thick sections were cut from the paraffin-embedded 
tissue blocks and stained with hematoxylin and eosin. Sections were immunohistochemically stained using 
an automated Bond Max stainer (Leica Biosystems; Melbourne, Australia). The following primary antibodies 
were used: polyclonal IgG (dilution 1:20,000; Dako, Glostrup, Denmark), IgG4 (HP6025, dilution 1:10,000; The 
Binding Site, Birmingham, UK), KIT/CD117 (A4502, dilution 1:600; Dako), IgE (A094, dilution 1:500; Dako), 
and high affinity IgE receptor (FcεRI) (Ab54411, dilution 1:500; Abcam, Cambridge, UK). Following immunohis-
tochemical staining, the number of IgG4- and IgG-positive cells were estimated in areas with the highest density 
of IgG4-positive cells. In accordance with the consensus statement on the pathological features of IgG4-RD3, 
three different high power fields (HPFs) (eyepiece: ×10, lens: ×40) were examined to calculate the average num-
ber of IgG4-positive cells per HPF and the IgG4-positive/IgG-positive cell ratio. IgE- and FcεRI-positive cells 
were counted in three different HPFs (eyepiece: ×10, lens: ×20) that were determined to have the highest density 
of positive cells. The average number of positive cells per HPF was calculated.
Dual immunofluorescence assays. For indirect dual immunofluorescence assays, paraffin sections were 
stained with the primary antibodies for IgE and FcεRI or FcεRI and c-kit. Fluorescein isothiocyanate-conjugated 
secondary antibodies (Alexa Fluor anti-mouse 555 and Alexa Fluor anti-rabbit 488; both from Life Technologies, 
Carlsbad, CA, USA) were used at a dilution of 1:400. The stained specimens were examined using a conventional 
immunofluorescence microscope (IX71; Olympus, Tokyo, Japan).
Statistical analysis. Data are presented as the means and standard deviations. All statistical analyses were 
performed using the Mann-Whitney U test in the Statistical Package for the Social Sciences for Windows, soft-
ware version 14.0 (SPSS Inc., Chicago, IL, USA). A P < 0.05 was considered statistically significant.
Results
Histological confirmation of IgG4-related lymphadenopathy. The clinicopathological characteris-
tics of the patients with IgG4-related lymphadenopathy are summarized in Table 1. The cohort was comprised of 
14 men and 9 women, with a median age of 61 (range, 45–82) years. Post-biopsy serum IgG or IgG4 levels were 
obtained for all patients except for Patient 23. On initial clinical examination, 14 patients presented with localized 
cervical lymphadenopathy. Seven patients had additional areas of lymphadenopathy (≥2) and 9 patients had 
extranodal lesions (e.g., in the salivary and lacrimal glands). All patients were followed up with regular imaging, 
laboratory assays, and clinical examinations. The median follow-up period was 42 (range, 2–154) months. During 
follow-up, 10 patients (43%) exhibited relapse in the residual lymph nodes or their disease had progressed to 
the development of other lymph nodes or extranodal lesions, including those of the submandibular and lacri-
mal glands. The average number of IgG- and IgG4-positive cells was 224.1 (range: 85.7–378) and 259.1 (range: 
97.7–437.3) per HPF, respectively. In all cases, the IgG4-positive/IgG-positive cell ratios were >60.0%. The aver-
age numbers of IgE and FcεRI strongly cytoplasmic positive cells were 3.83 (range: 85.7–378) and 8.50 (range: 
97.7–437.3) per HPF, respectively.
We confirmed that the tissue specimens from all 23 cases with IgG4-RD showed typical histological features of 
progressively transformed germinal center (PTGC)-type IgG4-related lymphadenopathy (Fig. 1A–F).
Histological features of non-specific lymphoid hyperplasia. The specimens exhibited multiple lym-
phoid follicle formations with moderate lymphocytic infiltration of interfollicular areas. Compared to the histo-
logical features of IgG4-related lymphadenopathy, those of non-specific lymphoid hyperplasia showed no PTGC, 
and less infiltration of plasma cells and/or eosinophils. Dermatopathic and autoimmune disease-associated 
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lymphadenopathies, including rheumatoid arthritis, systemic lupus erythematosus, and Sjögren’s syndrome, were 
excluded.
Clinical summary. The clinical differences between IgG4-related lymphadenopathy patients and those 
with non-specific lymphoid hyperplasia are shown in Table 2. The median age was 61 (range, 45–82) years for 
IgG4-related lymphadenopathy and 65 (range, 18–81) for non-specific lymphoid hyperplasia (P = 0.369). The 
Case 
No. Age Sex

































— Pollenosis,  rhinitis Yes 277 308.3 91.45 0.33 0.67 158* 1930*
2 66 M Cervical 16 Bilateral cervical — None Yes 235 266.3 87.5 4.33 5.33 89* 1511*




— None No 218 202 112.2 0.33 0 24* n.e.
4 45 F Cervical 21 Left cervical — Bronchilal  asthma No 186 212.3 91.14 0.33 1.33 18.3* 1202*
5 73 F Abdominal 30 Paraaortic, mesenteric — Drug No 85.7 97.7 90.05 1 1.67 16.5* 1206
6 51 F Cervical 21 Bilateral cervical — Asthma Yes 261 262.3 99.16 0.67 5.67 223* 1425
7 50 M Cervical 23 Right cervical — Allergic  rhinitis Yes 245 295.3 81.98 3 5 17.8* 1072*
8 46 M Cervical 13 Left cervical — None No 241 279.3 86.42 0 13.67 94.7* 1505*
9 71 M Cervical 18 Right cervical — Bronchilal  asthma No 378 258 152.2 1.67 1.67 58.7* 644*
10 67 M Cervical 19 Bilateral cervical, hilar Right lung
Allergic  
rhinitis Yes 218 297.7 73.83 5.33 10.33 389* 1619*
11 58 F Cervical 18 Right cervical
Bilateral 
parotid glands, 
left lobe of 
thyroid gland
Pollenosis No 188 282 78.76 3.67 33.72 51* 1297*
12 61 M Cervical 32 Bilateral cervical — None Yes 364 437.3 83.48 3 13 650* 2200*






Asthma Yes 230 339 68.74 13.33 23.67 1750* n.e.
14 70 M Cervical 10 Bilateral cervical Parotid gland, bilateral lungs None No 173 159.7 108.9 5.67 4.33 236* 1466*





— None Yes 219 346.3 65.02 1 0 12.7* 1542*










None Yes 267 283 94.43 1 1.33 n.e. 4057*
17 75 F Cervical 27 Left cervical — Asthma No 199 272.3 78.1 7 11.67 88.9* n.e.




None No 120 167 72.58 3.67 9 98.2* 1000*
19 72 M Cervical 25 Bilateral cervical — Drug No 220 278.3 79.13 8.67 11.67 71.2* 1201.7*
20 66 M Cervical 12 Right cervical
Right 
submandibular 
gland, left lobe 
of thyroid 
gland
None Yes 251 316.7 81.47 1.67 2.67 83.3* 1188.6*





Asthma No 218 204 110.9 4 2.67 630 2011




No 178 161.3 110.8 3.33 2.67 45* 900*
23 72 M Cervical 24 Cervical — None No 182 234 78.48 15 33.667 n.e. n.e.
Table 1. Histological and serological findings of patients with IgG4-related lymphadenopathy. M; male, F; 
female, LN; lymph node, n.e.; not examined. *; measurement of serum levels after biopsy.
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overall median age was 63 (range, 18–82). There was no significant difference in sex between the two groups 
(IgG4-related lymphadenopathy: 14 men and 9 women, non-specific lymphoid hyperplasia: 12 men and 11 
women; P = 0.562). Patients with IgG4-related lymphadenopathy had larger lymph nodes than patients with 
non-specific lymphoid hyperplasia (mean length, 21.1 [range, 6.0–35.0] vs. 12.3 [range, 5.0–26.0] mm, respec-
tively; P < 0.001). Lymphadenopathy occurred in the cervical region in 21 patients with IgG4-related lymphad-
enopathy and in 10 patients with non-specific lymphoid hyperplasia (91.3% vs. 43.5%, respectively; P < 0.001).
IgE and FcεRI staining patterns in IgG4-related lymphadenopathy. A large number of IgE- and 
FcεRI-positive cells were detected in the tissues of patients with IgG4-related lymphadenopathy and non-specific 
lymphoid hyperplasia (Supplementary Figures 1 and 2). In the non-specific lymphoid hyperplasia specimens, 
most mast cells stained for IgE and FcεRI with a surface membrane pattern (Figs 2A and 3A). In contrast, in the 
IgG4-related lymphadenopathy specimens, some mast cells stained for IgE and FcεRI with a strongly cytoplasmic 
pattern (Figs 2B and 3B). There was a greater number of strongly cytoplasmic IgE-positive cells in the IgG4-related 
lymphadenopathy specimens than in the non-specific lymphoid hyperplasia specimens (mean: 3.83 ± 3.99 vs. 
1.20 ± 1.79 cells per HPF, respectively; P = 0.007) (Fig. 2C). Strongly cytoplasmic FcεRI-positive cells were also 
Figure 1. Histological features of immunoglobulin G4 (IgG4)-related lymphadenopathy (Patient 19). (A) 
Lymph nodes showing multiple follicular hyperplasia with progressively transformed germinal centers 
(hematoxylin and eosin [H&E] staining, 20× magnification). (B) Irregular structure of a germinal center 
owing to the infiltration of small lymphocytes from the mantle zone (H&E staining, 100× magnification). 
(C) Abundant plasma cells infiltrating the germinal centers (H&E staining, 200× magnification). (D) Many 
eosinophils infiltrating the interfollicular zone (H&E staining, 200× magnification). (E,F) The majority of IgG4-
positive plasma cells are localized in the germinal centers. The IgG4-positive/IgG-positive plasma cell ratio is 
>70% (IgG4 and IgG immunostaining, 100× magnification).
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detected more frequently in the IgG4-related lymphadenopathy specimens than in the non-specific lymphoid 
hyperplasia specimens (mean: 7.14 ± 8.21 vs. 2.13 ± 3.03 cells per HPF, respectively; P = 0.011) (Fig. 3C).
Dual immunofluorescence assay. In the IgG4-related lymphadenopathy specimens, IgE and FcεRI 
staining exhibited a cytoplasmic granular pattern (Fig. 4A,B). Intracytoplasmic granules stained positive for IgE 
(green) and FcεRI (red), some of which overlapped as yellow spots. In the non-specific lymphoid hyperplasia 
specimens, IgE and FcεRI stained the surface membrane. These cells were positive for c-kit.
Discussion
Although many previous studies regarding IgG4-RD have been reported in the last decade, the pathogenesis of 
the disease remains unclear. Recent studies have reported that IgG4-RD is a Th2- and Treg-dominant disease, and 
IgG4-related lymphadenopathy Non-specific lymphoid hyperplasia P
Number 23 23 —
Age, years 61.5 (45–82) 57.3 (15–81) 0.37
Gender; male (%) 14 (60.9%) 12 (52.2%) 0.56
Size of lymph node (mm) 21.1 (6–35) 12.3 (5–26) 0.000025
Site of lymph node
 Cervical 21 (91.3%) 10 (43.5%) 0.00038
 Axillary 4 (17.4%) 6 (26.1%) 0.49
 Supraclavicular 3 (13.0%) 1 (0.043%) 0.31
 Hilar 4 (17.4%) 1 (0.043%) 0.16
 Inguinal 0 (0%) 5 (21.7%) 0.022
 Multiple 8 (34.8%) 6 (26.1%) 0.53
 Extranodal lesion 9 (39.1%) — —
(salivary gland, lacrimal gland, lung, etc.)
Table 2. Clinical characteristics of IgG4-related lymphadenopathy and non-specific lymphoid hyperplasia.
Figure 2. Staining for immunoglobulin E (IgE). (A) Mast cells exhibiting moderate-to-week IgE staining and 
a membranous localization in non-specific lymphoid hyperplasia. (B) In contrast, mast cells exhibit strong 
cytoplasmic staining for IgE in immunoglobulin G4-related lymphadenopathy (Patient 19). (C) The number 
of strongly cytoplasmic IgE-positive cells is counted in each high power field and was significantly larger in 
immunoglobulin G4-related lymphadenopathy than in non-specific lymphoid hyperplasia (*P < 0.01).
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the activation of these cytokines may be responsible for this disease5,6,9,10,12–15. However, studies investigating the 
mechanism underlying cytokine activation in IgG4-RD are few. In this study, we focused on mast cells exhibiting 
strong cytoplasmic staining for IgE.
Comprehensive diagnostic criteria consisted of elevated serum IgG4 concentrations (>135 mg/dl), but not 
in all cases3,16,17. Some patients with PTGC-type IgG4-related lymphadenopathy have normal serum IgG4 levels 
when measurements are obtained after biopsy, at which time there are no residual primary lesions18. In our cur-
rent data, serum IgG4 levels in 16 cases were <135 mg/dl. Furthermore, the recurrence ratio of IgG4-RD has been 
reported at 21.3%17. Some patients with PTGC-type IgG4-related lymphadenopathy have also experienced either 
persistence or relapse of residual lymph nodes18. In this study, 10 of 23 patients progressed to the development of 
other lymph nodes or extranodal lesions with elevated levels of serum IgG4.
Here, we confirmed that mast cells exhibiting strong cytoplasmic staining for IgE, were increased in 
IgG4-related lymphadenopathy. This is consistent with our previous report of submandibular gland disease9. 
Regarding the significance of strong cytoplasmic staining for IgE, we posit two hypotheses: overstaining and 
endocytosis.
IgG4-RD is frequently complicated by allergic conditions19,20. We previously reported that 52% of patients 
with IgG4-related lymphadenopathy also had allergic disease18. Our current study showed that 15 of 19 (78.9%) 
patients examined had allergic conditions. Furthermore, elevation of serum IgE levels, defined as IgE >250 IU/
ml, was observed in more than half of patients with IgG4-RD17, suggesting that strong cytoplasmic staining for 
IgE might indicate only overstaining. However, this study confirmed that mast cells exhibiting strong cytoplasmic 
staining for FcεRI also increased, as did staining for IgE.
Recent reports have shown that the activation of mast cells leads to internalization of IgE and FcεRI21,22. 
Accordingly, we added dual immunofluorescence assays, resulting in IgE and FcεRI staining exhibited as multi-
ple cytoplasmic granules, some of which overlapped in IgG4-related lymphadenopathy. In contrast, staining in 
non-specific lymphoid hyperplasia was localized to the surface membrane. These results showed that the signif-
icance of strong cytoplasmic staining for IgE and FcεRI might reflect the internalization of IgE and FcεRI due to 
mast cell activation in IgG4-RD. Mast cells are activated by various biological substances (e.g., exogenous stimuli, 
endogenous peptides, chemokines, components of the complement system, and Fc receptors for IgE), leading 
to degranulation and the production of mediators such as cytokines and eicosanoids23. Some previous studies 
have suggested that response to antigen presentation might be involved in the pathogenesis of IgG4-RD20,24–26. 
Our current study suggests that some antigens might activate mast cells. However, additional assays are needed 
Figure 3. Staining pattern of high affinity immunoglobulin E (IgE) receptor (FcεRI) is similar to that of IgE. 
(A) Infiltrating mast cells in non-specific lymphoid hyperplasia exhibit weak membranous FcεRI staining. 
(B) In contrast, infiltrating mast cells in immunoglobulin G4-related lymphadenopathy exhibit strong 
cytoplasmic staining (Patient 19). (C) Strongly cytoplasmic FcεRI-positive cells are significantly increased in 
immunoglobulin G4-related lymphadenopathy as compared to those in non-specific lymphoid hyperplasia 
(*P = 0.01).
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to elucidate the functional significance of IgE and FcεRI internalization. Although previous reports clarified 
the internalized FcεRI trafficking in early endosomes23, no published reports have investigated the trafficking 
completely.
Other Th subsets (T follicular helper cells or CD4+ cytotoxic T lymphocytes) and other immune cells (M2 
macrophages) have recently been reported to participate in the pathogenesis of IgG4-RD20,25,27–29. Mattoo et al.25 
reported prominent clonal expansions of CD4+ SLAMF7+ cytotoxic T lymphocytes but not CD4+GATA3+ 
memory Th2 cells in patients with IgG4-RD. This strongly suggests that these cytotoxic T lymphocytes expanded 
in response to a specific causal antigen. Furukawa et al.29. suggested that M2 macrophages producing IL-33 are 
deeply involved in the activation of Th2 immune responses in IgG4-RD. Therefore, IgG4-RD might progress via 
the interconnected network of various Th subsets or immune cells.
In conclusion, we confirmed that mast cells exhibiting strong cytoplasmic staining for IgE and FcεRI were 
increased in IgG4-related lymphadenopathy, implying the activation of mast cells. Since mast cells “communi-
cate” with various cells to produce a mediator, a better understanding of the role of mast cells could enable us to 
understand the pathogenesis of IgG4-RD.
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